FDA approves sNDA for ERLEADA® (apalutamide) for treatment of patients with mCSPC
Janssen announced the FDA has approved ERLEADA® (apalutamide) for treatment of patients with metastatic castration-sensitive prostate cancer. The new indication will make this androgen receptor inhibitor available for the approximately 40,000 people in the U.S. diagnosed with mCSPC annually. September 18, 2019